Cosmo N.V. (CMOPF)
| Market Cap | 1.16B -12.1% |
| Revenue (ttm) | 117.32M -43.7% |
| Net Income | -7.26M |
| EPS | -0.44 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 900.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,095 |
| Open | 65.73 |
| Previous Close | 71.90 |
| Day's Range | 65.73 - 69.97 |
| 52-Week Range | 63.50 - 169.90 |
| Beta | 1.47 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 23, 2026 |
About Cosmo
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ... [Read more]
News
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) (“Cosmo”) announced today that it will publish its Half-Year 2026 results on Thursday, 23 July 2026 at 7:00 am CEST.
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo”) is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned sub...
Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition…